Common genetic variants identify targets for COVID-19 and individuals at

high risk of severe disease

J. E. Horowitz[1†], J. A. Kosmicki[1†], A. Damask[1†], D. Sharma[1], G. H. L. Roberts[2], A. E. Justice[3], N.

Banerjee[1], M. V. Coignet[2], A. Yadav[1], J. B. Leader[3], A. Marcketta[1], D. S. Park[2], R. Lanche[1], E.

Maxwell[1], S. C. Knight[2], X. Bai[1], H. Guturu[2], D. Sun[1], A. Baltzell[2], F. S. P. Kury[1], J. D. Backman[1],

A. R. Girshick[2], C. O'Dushlaine[1], S. R. McCurdy[2], R. Partha[2], A. J. Mansfield[1], D. A. Turissini[2],

A. H. Li[1], M. Zhang[2], J. Mbatchou[1], K. Watanabe[1], L. Gurski[1], S. E. McCarthy[1], H. M. Kang[1], L.

Dobbyn[1], E. Stahl[1], A. Verma[4], G. Sirugo[4], Regeneron Genetics Center*, M. D. Ritchie[4], M.

Jones[1], S. Balasubramanian[1], K. Siminovitch[1], W. J. Salerno[1], A. R. Shuldiner[1], D. J. Rader[4], T.

Mirshahi[3], A. E. Locke[1], J. Marchini[1], J. D. Overton[1], D. J. Carey[3], L. Habegger[1], M. N. Cantor[1],

K. A. Rand[2], E. L. Hong[2], J. G. Reid[1], C. A. Ball[2], A. Baras[1‡], G. R. Abecasis[1‡], M. A. Ferreira[1‡]

From:

[1]Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA

[2]AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043, USA

[3]Geisinger, Danville, PA, 17822, USA

[4]Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia,

PA, 19104, USA

*A complete list of investigators is provided in the Supplementary Appendix.

[†] J. E. Horowitz, J. A. Kosmicki and A. Damask contributed equally to this manuscript.

[‡]A. Baras, G. R. Abecasis and M. A. Ferreira jointly supervised this work.

Correspondence to: manuel.ferreira@regeneron.com

ABSTRACT

The need to identify and effectively treat COVID-19 cases at highest risk for severe disease remains critical. We identified five common genetic loci (two novel) that modulate both COVID-19 susceptibility and severity, implicating *TMPRSS2*, *IFNAR2, CCHCR1*, *TCF19* and *SLC6A20* as potential targets. A high genetic burden was strongly associated with increased risk of hospitalization and severe disease among COVID-19 cases, especially among individuals with few known clinical risk factors.

MAIN TEXT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] causes coronavirus disease 2019 (COVID-19)[2], which has lead to >2 million recorded deaths worldwide since December 2019 [3]. Reported risk factors for severe COVID-19, defined here as death or hospitalization combined with respiratory failure [4], include male sex, older age, race, obesity, kidney, cardiovascular and respiratory diseases [5-9]. Corticosteroids, repurposed biologics and anti-viral medicines, as well as antibody therapies have been authorized to treat COVID-19 [10-14]. Presently, excess mortality due to COVID-19 is high and the urgent need for therapies that treat or prevent severe disease remains. Further, identifying individuals at highest risk of adverse outcomes may help prioritize individuals for vaccines [15, 16] or monoclonal antibody treatments [17, 18], which are currently in short supply. In this study, we used human genetics to identify potential targets for severe COVID-19 and developed genetic risk scores to identify individuals at highest risk of severe disease with greater precision than can be attained with clinical and demographic variables alone.

We performed genetic association studies of COVID-19 outcomes across 20,177 individuals with COVID-19 and 653,646 individuals with no record of SARS-CoV-2 infection aggregated from four studies (**Supplementary Table 1**) and five ancestries (Admixed American, African, European, South Asian and East Asian). Of the COVID-19 cases, 3,056 (15%) were hospitalized and 1,034 (5%) had severe disease; hospitalized patients were more likely to be older, of non-European ancestry and to have pre-existing cardiovascular and lung disease (**Supplementary Table 2)**. Using these data, we defined two groups (risk and severity) of COVID-19 outcomes: five phenotypes related to disease risk and two phenotypes related to disease severity among

COVID-19 cases (**Supplementary Table 3).** For each phenotype, when >25 cases were available,

we performed ancestry-specific genetic analyses in each study and then combined results across

studies and ancestries using a fixed-effects meta-analysis. Genomic inflation factors (λ_{GC}) for the

meta-analyses were all less than 1.05, suggesting no substantial impact of population structure or

unmodeled relatedness (**Supplementary Table 4).**

To identify genetic variants that modulate disease severity following SARS-CoV-2 infection, we

focused on first replicating eight independent associations (r^2<0.05) with disease risk reported in

recent GWAS that included >1,000 cases [19-22] (**Supplementary Table 5**) and then explored

the impact of these variants on disease severity. After accounting for multiple testing, five variants

had a significant (P<0.0012) and directionally consistent association with at least one of our five

disease risk phenotypes (**Supplementary Table 6**): rs73064425:T in *LZTFL1* (strongest in

comparison between COVID-19 hospitalized cases vs. COVID-19 negative or unknown controls;

MAF=7%, OR=1.37, P=1x10^{-11}); rs2531743:G near *SLC6A20* (COVID-19 positive vs. COVID-

19 negative; MAF=42%, OR=0.94, P=2x10^{-6}); rs143334143:A in the MHC (COVID-19 severe

vs. COVID-19 negative or unknown; MAF=7%, OR=1.32, P=3x10^{-4}); rs9411378:A in *ABO*

(COVID-19 positive vs. COVID-19 negative or unknown; MAF=24%, OR=1.12, P=2x10^{-10}); and

rs2236757:A in *IFNAR2* (COVID-19 hospitalized   vs. COVID-19 negative or unknown;

MAF=29%, OR=1.13, P=3x10^{-5}). Effect sizes were comparable across ancestries

(**Supplementary Table 7**). Of note, nominally significant and directionally consistent associations

were observed with the remaining three published risk variants (in/near *OAS3*, *DPP9* and

RAVER1; **Supplementary Table 6**), suggesting these associations likely represent true-positives.

Having established these five variants (in/near *LZTFL1*, *SLC6A20*, MHC, *ABO* and *IFNAR2*) as

bona fide risk factors for COVID-19, we then asked which (if any) of these variants were also

associated with severity amongst COVID-19 cases. Among these five variants, three were

significantly (*P*<0.05) associated with worse outcomes among infected individuals (**Figure 1A**

and **Supplementary Table 8**), while rs9411378 in *ABO* and rs2531743 near *SLC6A20* did not

associate with COVID-19 severity (**Figure 1B**). Collectively, these results highlight three variants

(in/near *LZTFL1*, *MHC* and *IFNAR2*) associated with both COVID-19 susceptibility and worse

disease outcomes, including respiratory failure and death. These variants may be used to identify

individuals at risk of severe COVID-19 and suggest nearby genes may represent targets for

therapeutic intervention.

We next looked for novel genetic associations with severe COVID-19. No new associations at

$P<5 \times 10^{-8}$ were observed across our two severity phenotypes (hospitalized vs. non-hospitalized

cases; severe vs. non-hospitalized cases; **Supplementary Figure 1**), suggesting these analyses

were underpowered for genome-wide discovery. To increase power, we combined results from our

COVID-19 hospitalization phenotype (3,056 cases vs. 653,022 controls) with data from three

publicly available GWAS (FinnGen[19], Ellinghaus et al.[20] and GenOMICC[21]) for a

combined sample size of 6,993 hospitalized cases and 904,801 controls with no record of SARS-

CoV-2 infection. In this larger analysis of hospitalization risk, seven independent variants in six

loci reached genome-wide significance (**Figure 2**), including five variants that were reported in

previous GWAS (*LZTFL1* [two variants], MHC, *DPP9* and *IFNAR2*) and two novel associations

(**Table 1**): rs9903642 near *KAT7* (5q34; MAF=4%, OR=1.32, $P=1.4 \times 10^{-8}$), which is required for

the generation and maintainenace of peripheral T cells [23]; and rs2298661 in *TMPRSS2* (16q24.3;

MAF=22%, OR=0.87, P=1.9x10^{-8}), a host protease that promotes SARS-CoV-2 entry [24].

Consistent associations were observed across studies and ancestries for the *KAT7* and *TMPRSS2*

variants (**Supplementary Figure 2**). We then assessed the association between each of these two

novel variants and disease severity and found that the risk alleles for both were overrepresented

(P<0.05) amongst hospitalized cases (**Figure 1C and Supplementary Table 9**). Therefore, our

two novel susceptibility loci for COVID-19 risk are also associated with increased risk of worse

disease outcomes.

Collectively, our association analyses highlighted five common variants: three known (in/near

LZTFL1, MHC, *IFNAR2*) and two novel (in/near *KAT7*, *TMPRSS2*) associated with COVID-19

susceptibility (P<5x10^{-8}) as well as disease severity among cases (P<0.05). As all five variants are

either intronic or intergenic, it is not immediately clear how these variants influence gene function.

To help identify gene targets, and thus potential therapeutic targets for severe COVID-19, we

searched for functional protein-coding variants (missense or predicted loss-of-function) in high

LD (r^2>0.80) with each variant. We found nine functional variants in six genes (**Supplementary**

Table 10): *TMPRSS2*, discussed in greater detail below; *IFNAR2*, a cytokine receptor component

in the anti-viral type 1 interferon pathway, which is activated by SARS-CoV-2 and is dysregulated

in severe COVID-19 cases [25-27]; *CCHCR1*, a P-body protein associated with cytoskeletal

remodeling and mRNA turnover [28, 29], which can interact with human papillomavirus-16 [30,

31]; *TCF19*, a transcription factor associated with hepatitis B [32, 33]; and *C6orf15* and

PSORS1C1, two functionally uncharacterized genes in the MHC that are genetically associated

with autoimmunity [34]. These data indicate that the risk variants we identified may have

functional effects on these six genes.

Next, we asked if the sentinel risk variants co-localized (*i.e.* were in high LD, $r^2>0.80$) with published sentinel expression quantitative trait loci (eQTL) across 52 studies (**Supplementary Table 11**), specifically focusing on 121 genes in *cis* (± 500 kb). We found co-localization with sentinel eQTL for seven genes (**Supplementary Table 12)**: *CCR2* (eQTL from blood), a monocyte-expressed chemokine receptor upregulated in COVID-19 [35-37] and ARDS [38]; *SLC6A20* (lung), a proline transporter that binds the host SARS-CoV-2 receptor, angiotensin-converting enzyme 2 [39]; *IFNAR2* and *TCF19* (multiple tissues), both discussed above*; LST1* (blood)*,* an immune modulatory protein that inhibits lymphocyte proliferation [40] and is upregulated in response to bacterial ligands [41]; *HLA-C* (adipose), a natural killer cell ligand, associated with viral infection [42] and autoimmunity [43]; and *IL10RB* (multiple tissues), a pleotropic cytokine receptor associated with persistent hepatitis B and autoimmunity [44, 45]. Collectively across missense and regulatory variants, these analyses identified 11 specific putative effector genes in COVID-19 risk loci, though functional studies are required to confirm these predictions.

Of these 11 putative target genes, *TMPRSS2* stands out because of its demonstrated role in promoting viral infections. *TMPRSS2* encodes a host protease that cleaves viral surface glycoproteins to promote viral entry, including those from influenza hemagglutinin [46] and both Middle East respiratory syndrome-related coronavirus [47] and SARS-CoV-1 spike proteins [48]. Further, *Tmprss2* deficient mice show reduced viral spread and immunopathology in the lungs in response to coronavirus infection [49], and SARS-CoV-2 viral entry is blocked by protease inhibitors that inhibit *TMPRSS2* activity [24]. These observations suggest that inhibition of

TMPRSS2 might be protective against COVID-19. Consistent with this hypothesis, we found that

the missense variant that was associated with protection from COVID-19 (rs12329760, p.V160M;

Supplementary Table 11) is predicted to be deleterious by SIFT [50], PolyPhen2-HVAR and

PolyPhen2-HDIV [51] and is also predicted to decrease protein stability in structural models [52,

53]. These results provide human genetic support for loss of *TMPRSS2* in SARS-CoV-2 infection

and suggest that TMPRSS2 blockade might protect against worse COVID-19 outcomes.

The second aim of this study was to determine if common genetic variants can help identify

individuals at high risk of severe disease, who may be prioritized for prophylactic or therapeutic

interventions. Specifically, we focused on the three variants (in/near *LZTFL1*, MHC and *IFNAR2*)

with confirmed association with COVID-19 susceptibility and that also modulate COVID-19

severity. Using these variants, we created a weighted genetic risk score (GRS) for individuals with

COVID-19 and then compared the risk of hospitalization and severe disease between those with a

high GRS and all other cases, after adjusting for established risk factors (*e.g.* age, sex,

comorbidities). The weights used for each variant corresponded to the effect size (log of the odds

ratio) reported in previous GWAS. When considering COVID-19 cases of European ancestry

(N=16,467), we found that having a high GRS (top 10%) was associated with a 1.45-fold increased

risk of hospitalization (95% CI 1.25-1.69, $P=2 \times 10^{-6}$; **Figure 3A**) and 1.88-fold increased risk of

severe disease (95% CI 1.51-2.35, $P=3 \times 10^{-8}$; **Figure 3B**). A consistent pattern was observed in

other ancestries, though sample sizes were considerably smaller (**Supplementary Tables 13** and

14).

We then compared the effect of the GRS between individuals with and without established risk

factors for severe COVID-19. In both the AncestryDNA and UK Biobank studies, we found that

a high GRS (top 10%) was associated with risk of severe disease both among individuals with and

without established clinical risk factors for severe COVID-19 (**Figure 4**). In the meta-analysis of

the two studies, a high GRS was associated with a 1.79-fold (95% CI 1.37-2.33, $P=2x10^{-5}$) and

2.42-fold (95% CI 1.65-3.55, $P=6x10^{-6}$) higher risk of severe disease, respectively among

individuals with and without established risk factors (**Supplementary Table 15**). There was no

evidence for heterogeneity of GRS effect with clinical risk factor status ($P=0.21$). Similar results

were observed for risk of hospitalization (**Supplementary Figure 3** and **Supplementary Table**

15) and when including in the GRS all eight variants reported to associate with COVID-19

susceptibility in previous GWAS (**Supplementary Figure 4**). Collectively, these results

demonstrate that a GRS calculated using variants associated with disease risk and severity can be

used to identify COVID-19 cases at high risk of developing poor disease outcomes. This is

important as many of these individuals might benefit from prioritization for prophylactic or

therapeutic interventions [54].

In summary, we confirmed five common variant associations with COVID-19 susceptibility and

further show that three of these variants modulate disease severity among cases. We also identified

two novel associations with both disease susceptibility and severity, one of which provides human

genetic support for TMPRSS2 blockade in protection from COVID-19. Lastly, we demonstrate

that a genetic risk score based on common variants validated in this study can be used to identify

individuals at high risk of poor disease outcomes. Collectively, our results point to potential novel

targets for COVID-19 and can be applied to predict severe outcomes in COVID-19 patients.

ONLINE METHODS

<u>**Participating Studies**</u>

AncestryDNA COVID-19 Research Study. AncestryDNA customers over age 18, living in the

United States, and who had consented to research, were invited to complete a survey assessing

COVID-19 outcomes and other demographic information. These included SARS-CoV-2 swab and

antibody test results, COVID-19 symptoms and severity, brief medical history, household and

occupational exposure to SARS-CoV-2, and blood type. A total of 83,930 AncestryDNA survey

respondents were selected for inclusion in this study [55]. Respondents selected for this study

included all individuals with a positive COVID-19 test together with age and sex matched controls.

DNA samples were genotyped as described previously[55]. Genotype data for variants not

included in the array were then inferred using imputation to the Haplotype Reference Consortium

(HRC) reference panel. Briefly, samples were imputed to HRC version 1.1, which consists of

27,165 total individuals and 36 million variants. The HRC reference panel does not include indels;

consequently, indels are not present in the imputed data. We determined best-guess haplotypes

with Eagle version 2.4.1 and performed imputation with Minimac4 version 1.0.1. We used

1,117,080 unique variants as input and 8,049,082 imputed variants were retained in the final data

set. Variants with a Minimac4 $R^2<0.30$ were filtered from the analysis.

Geisinger Health System (GHS). The GHS MyCode Community Health Initiative is a health

system-based cohort from central and eastern Pennsylvania (USA) with ongoing recruitment since

2006[56]. A subset of 144,182 MyCode participants sequenced as part of the GHS-Regeneron

Genetics Center DiscovEHR partnership were included in this study. Information on COVID-19

outcomes were obtained through GHS's COVID-19 registry. Patients were identified as eligible

for the registry based on relevant lab results and ICD-10 diagnosis codes; patient charts were then

reviewed to confirm COVID-19 diagnoses. The registry contains data on outcomes, comorbidities,

medications, supplemental oxygen use, and ICU admissions. DNA from participants was

genotyped on either the Illumina OmniExpress Exome (OMNI) or Global Screening Array (GSA)

and imputed to the TOPMed reference panel (stratified by array) using the TOPMed Imputation

Server. Prior to imputation, we retained variants that had a MAF >= 0.1%, missingness < 1% and

HWE p-value > 10^{-15}. Following imputation, data from the OMNI and GSA datasets were merged

for subsequent association analyses, which included an OMNI/GSA batch covariate, in addition

to other covariates described below.

Penn Medicine BioBank (PMBB) study. PMBB study participants are recruited through the

University of Pennsylvania Health System (UPHS), which traditionally enrolled participants

during hospital or clinic visits. Due to COVID-19, recruitment pivoted to electronic consenting.

Participants donate blood or tissue and allow access to EHR information [57]. Patients were

identified through the UPHS COVID-19 registry, and subsequently invited to participate in

PMBB. The PMBB COVID-19 registry consists of patients who have positive qPCR testing for

SARS-COV-2 and also enrolled in PMBB. We then used electronic health records to classify

COVID-19 patients into hospitalized and severe (ventilation or death) categories. DNA genotyping

was performed with the Illumina Global Screening Array, and imputation performed using the

TOPMed reference panel as described for GHS above.

UK Biobank (UKB) study. We studied the host genetics of SARS-CoV-2 infection in participants

of the UK Biobank study, which took place between 2006 and 2010 and includes approximately

500,000 adults aged 40-69 at recruitment. In collaboration with UK health authorities, the UK

Biobank has made available regular updates on COVID-19 status for all participants, including

results from four main data types: qPCR test for SARS-CoV-2, anonymized electronic health

records, primary care and death registry data. We report results based on phenotype data

downloaded on the 4th January 2021 and excluded from the analysis 28,547 individuals with a

death registry event prior to 2020. DNA samples were genotyped as described previously [58]

using the Applied Biosystems UK BiLEVE Axiom Array (N=49,950) or the closely related

Applied Biosystems UK Biobank Axiom Array (N=438,427). Genotype data for variants not

included in the arrays were inferred using the TOPMed reference panel, as described above.

COVID-19 phenotypes used for genetic association analyses

We grouped participants from each study into three broad COVID-19 disease categories

(**Supplementary Table 1**): (i) positive – those with a positive qPCR or serology test for SARS-

CoV-2, or a COVID-19-related ICD10 code (U07), hospitalization or death; (ii) negative – those

with only negative qPCR or serology test results for SARS-CoV-2 and no COVID-19-related

ICD10 code (U07), hospitalization or death; and (iii) unknown – those with no qPCR or serology

test results and no COVID-19-related ICD10 code (U07), hospitalization or death. We then used

these broad COVID-19 disease categories, in addition to hospitalization and disease severity

information, to create seven COVID-19-related phenotypes for genetic association analyses, as

detailed in **Supplementary Table 3**. For association analysis in the AncestryDNA study, we

excluded from the COVID-19 unknown group individuals who had (i) a first-degree relative who

was COVID-19 positive; or (ii) flu-like symptoms.

Genetic association analyses

Association analyses in each study were performed using the genome-wide Firth logistic regression test implemented in REGENIE [59]. In this implementation, Firth's approach is applied when the p-value from standard logistic regression score test is below 0.05. We included in step 1 of REGENIE (*i.e.* prediction of individual trait values based on the genetic data) directly genotyped variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-Weinberg equilibrium test P-value$>10^{-15}$ and linkage-disequilibrium (LD) pruning (1000 variant windows, 100 variant sliding windows and $r^2<0.9$). The association model used in step 2 of REGENIE included as covariates age, age^2, sex, age-by-sex, and the first 10 ancestry-informative principal components (PCs) derived from the analysis of a stricter set of LD-pruned (50 variant windows, 5 variant sliding windows and $r^2<0.5$) common variants from the array (imputed for the GHS study) data.

Within each study, association analyses were performed separately for five different continental ancestries defined based on the array data: African (AFR), Admixed American (AMR), European (EUR) and South Asian (SAS). We determined continental ancestries by projecting each sample onto reference principle components calculated from the HapMap3 reference panel. Briefly, we merged our samples with HapMap3 samples and kept only SNPs in common between the two datasets. We further excluded SNPs with MAF<10%, genotype missingness >5% or Hardy-Weinberg Equilibrium test p-value $< 10^{-5}$. We calculated PCs for the HapMap3 samples and projected each of our samples onto those PCs. To assign a continental ancestry group to each non-HapMap3 sample, we trained a kernel density estimator (KDE) using the HapMap3 PCs and used the KDEs to calculate the likelihood of a given sample belonging to each of the five continental ancestry groups. When the likelihood for a given ancestry group was >0.3, the sample

was assigned to that ancestry group. When two ancestry groups had a likelihood >0.3, we

arbitrarily assigned AFR over EUR, AMR over EUR, AMR over EAS, SAS over EUR, and AMR

over AFR. Samples were excluded from analysis if no ancestry likelihoods were >0.3, or if more

than three ancestry likelihoods were > 0.3.

Results were subsequently meta-analyzed across studies and ancestries using an inverse

variance-weighed fixed-effects meta-analysis.

Identification of putative targets of GWAS variants based on colocalization with eQTL

We identified as a likely target of a sentinel GWAS variant any gene for which a sentinel

expression quantitative trait locus (eQTL) co-localized (*i.e.* had LD $r^2 > 0.80$) with the sentinel

GWAS variant. That is, we only considered genes for which there was strong LD between a

sentinel GWAS variant and a sentinel eQTL, which reduces the chance of spurious colocalization.

Sentinel eQTL were defined across 174 published datasets (**Supplementary Table 10**), as

described previously [60]. We did not use statistical approaches developed to distinguish

colocalization from shared genetic effects because these have very limited resolution at high LD

levels ($r^2 > 0.80$) [61].

Genetic risk score (GRS) analysis of COVID-19 hospitalization and severity

First, in each study (AncestryDNA, GHS, UKB and PMBB), we created a GRS for each COVID-

19 positive individual based on variants that were reported to associate with COVID-19

susceptibility in previous GWAS and that we (i) independently replicated; and (ii) found to be

associated with COVID-19 severity. We used as weights the effect (beta) reported in previous

GWAS (**Supplementary Table 5**). Second, we ranked COVID-19 individuals based on the GRS

and created a new binary GRS predictor by assigning each individual to a high (top 5%) or low

(rest of the population) percentile group. Third, for studies with >100 hospitalized cases, we used

logistic regression to test the association between the binary GRS predictor and risk of

hospitalization (hospitalized cases vs. all other cases), including as covariates age, sex, age-by-sex

interaction, and ten ancestry-informative PCs. In addition to age and sex, we included as additional

covariates established clinical risk factors for COVID-19 that are outlined in the Emergency Use

Authorisation treatment guidelines for casirivimab and imdevimb: BMI, chronic kidney disease,

diabetes, immunosuppressive disease, chronic obstructive pulmonary disease or other chronic

respiratory disease, cardiovascular disease and hypertension. We repeated the association analysis

(i) using different percentile cut-offs for the GRS (5%, 10%, 20%, 30% and 40%); and (ii) to test

the association with disease severity (severe cases vs. all other cases). We then stratified COVID-

19 cases by clinical risk (high versus lower) and evaluated the association between the top 10%

by GRS (i.e. high genetic risk) and risk of hospitalization or severe disease. The stratified analyses

were performed with logistic regression, with sex and ancestry-informative PCs included as

covariates. High clinical risk was defined as any one of the following: (i) age$\geq$65; (ii) BMI$\geq$35;

(iii) chronic kidney disease, diabetes or immunosuppressive disease; (iv) age $\geq$55 and presence of

chronic obstructive pulmonary disease/other chronic respiratory disease, cardiovascular disease,

or hypertension.

<u>Results availability</u>

All genotype-phenotype association results reported in this study are available for browsing using

the RGC's COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use

is limited to research purposes in accordance with the Terms of Use (https://rgc-

covid19.regeneron.com/terms-of-use).

Competing interests

J.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., D.S., F.S.P.K., J.D.B., C.O'D.,

A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, H.M.K., L.D., E.S., M.J., S.B., K.S.M, W.J.S.,

A.R.S., A.E.L., J.M., J.O., L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees

and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. G.H.L.R.,

M.V.C., D.S.P., S.C.K. A.Bal., A.R.G., S.R.M., R.P., M.Z., K.A.R., E.L.H., C.A.B. are current

employees at AncestryDNA and may hold equity in AncestryDNA. The other authors declare no

competing interests.

Acknowledgements

342 This research has been conducted using the UK Biobank Resource (Project 26041). The Penn

343 Medicine BioBank is funded by a gift from the Smilow family, the National Center for Advancing

344 Translational Sciences of the National Institutes of Health under CTSA Award Number

345 UL1TR001878, and the Perelman School of Medicine at the University of Pennsylvania. We want

346 to acknowledge the participants and investigators of the FinnGen study.

FIGURES

Figure 1. Comparison of effect sizes across COVID-19 susceptibility and severity outcomes

for five previously reported (A, B) and two novel (C) risk variants.

(A, B) Five variants that were reported to associated with COVID-19 susceptibility in previous

studies and replicated in our analysis. Of these, three variants also associated with disease severity

among COVID-19 cases (in/near *LZTFL1*, *CCHCR1* and *IFNAR2*; panel A), whereas two variants

did not (in *ABO* and *SLC6A20*, panel B).

(C) Two novel risk variants for COVID-19 discovered in the trans-ancestry meta-analysis of risk

of COVID-19 hospitalization across seven studies (AncestryDNA, GHS, UKB, PMBB, FinnGen,

Ellinghaus et al. and Pairo-Castineira et al).

Figure 2. Summary of association results from the trans-ancestry meta-analysis of risk of COVID-19 hospitalization. The meta-analysis included results from seven studies (AncestryDNA, GHS, UKB, PMBB, FinnGen, Ellinghaus et al. and Pairo-Castineira et al. and five ancestries (AFR, AMR, EUR, SAS and EAS), totaling 6,993 hospitalized cases and 904,801 controls with no record of SARS-CoV-2 infection.

A. Risk of hospitalization

B. Risk of severe disease

Figure 3. Association between a three-SNP genetic risk score (GRS) and risk of hospitalization (A) and severe disease (B) among COVID-19 cases of European ancestry.

(A) Association between high genetic risk and hospitalization. Risk of hospitalization among cases is shown for individuals in the top GRS percentile, agnostic to the number of clinical risk factors present. The association was tested in three studies separately (AncestryDNA, UKB and GHS studies) using logistic regression, with established risk factors for COVID-19 included as covariates (see Methods for details). Results were then meta-analyzed across studies, for a combined sample size of 16,917 COVID-19 cases, including 2,640 hospitalized. N in red: number of COVID-19 cases in the top GRS percentile.

(B) Association between high genetic risk and severe disease. The association was tested as described above in two studies separately (AncestryDNA and UKB studies). Results were then meta-analyzed across studies, for a combined sample size of 16,048 COVID-19 cases, including 816 with severe disease.

383   N in red: number of COVID-19 cases in the top GRS percentile. N in grey: number of COVID-19

384   cases in the rest of population.

A. AncestryDNA study

B. UK Biobank study

Figure 4. Association between a three-SNP genetic risk score (GRS) and risk of severe disease

among COVID-19 cases of European ancestry after stratifying by the presence of clinical

risk factors.

(A) Rate of severe disease in the AncestryDNA study (8,835 COVID-19 cases, including 287 with

severe disease).

(B) Rate of severe disease in the UK Biobank study (7,213 COVID-19 cases, including 529 with

severe disease).

High genetic risk (red bars): top 10% of the GRS. Low genetic risk (grey bars): bottom 90% of the

GRS (*i.e.* all other COVID-19 cases).

TABLES

Table 1. Top associations identified in the trans-ancestry meta-analysis of risk of COVID-19

hospitalization. The meta-analysis included results from seven studies (AncestryDNA, GHS,

UKB, PMBB, FinnGen [19], Pairo-Castineira et al. [20] and Ellinghaus et al. [21]) and five

ancestries (AFR, AMR, EUR, SAS and EAS), totaling 6,993 hospitalized cases and 904,801

controls with no record of SARS-CoV-2 infection.

Nearest gene	rsID	Position hg38	Effect allele	Odds ratio* (95% CI)	P-value	N cases (N with 0|1|2 copies of the effect allele)	N controls (N with 0|1|2 copies of the effect allele)	Effect allele frequency
Independent associations in previously reported risk loci								
LZTFL1	rs9814578	3:45821775:T:G	G	0.891 (0.855, 0.928)	2.68E-08	6993 (2160|3357|1467)	904801 (239479|446973|218337)	0.488
LZTFL1	rs67959919	3:45830416:G:A	A	1.602 (1.497, 1.714)	3.36E-42	6662 (5191|1363|102)	903146 (776403|121415|5321)	0.073
CCHCR1	rs111837807	6:31153455:T:C	C	1.272 (1.187, 1.364)	1.33E-11	6844 (5704|1075|59)	904056 (780913|118381|4754)	0.071
DPP9	rs2277732	19:4723658:C:A	A	1.171 (1.121, 1.223)	1.34E-12	6993 (3140|3028|819)	904801 (444323|378278|82190)	0.300
IFNAR2	rs2252639	21:33245424:A:G	A	1.192 (1.142,1.242)	2.46E-16	6993 (2871|3175|938)	904801 (423900|389958|90935)	0.316
Independent associations in putative novel risk loci								
KAT7	rs9903642	17:49791559:G:A	A	1.316 (1.197, 1.447)	1.40E-08	6756 (6043|687|19)	903616 (838183|63992|1434)	0.037
TMPRSS2	rs2298661	21:41473715:C:A	A	0.869 (0.827, 0.912)	1.92E-08	6993 (4550|2186|247)	904801 (548976|311126|44691)	0.221

403   * Estimated based on trans-ancestry inverse-variance meta-analysis across UKB, AncestryDNA, GHS, UPENN-PMBB and three publicly available GWAS (FinnGen, Ellinghaus et al., Pairo-Castineira et al.
404

 SUPPLEMENTARY FIGURES

Provided in a separate file.

Supplementary Figure 1. Summary of association results from the meta-analysis of two
phenotypes related to disease severity among COVID-19 cases. **(A)** Phenotype COVID-19
positive hospitalized (N=3,056) vs COVID-19 positive and not hospitalized (N=17,018). **(B)**
Phenotype COVID-19 positive severe (N=1,007) vs COVID-19 positive and not hospitalized
(N=16,919).

Supplementary Figure 2. Two putative novel loci identified in the trans-ancestry meta-
analysis of risk of COVID-19 hospitalization. (A) rs9903642 (17:49791559:G:A, effect allele
A) at 17q21.33, near *KAT7*. **(B)** rs2298661 (21:41473715:C:A, effect allele A) at 21q22.3 in
TMPRSS2. RR: number of individuals homozygous for reference allele. RA: number of
heterozygous individuals. RA: number of individuals homozygous for alternative (effect) allele.
AAF: alternative allele frequency. OR: odds ratio.

Supplementary Figure 3. Association between a three-SNP genetic risk score (GRS) and risk
of hospitalization among COVID-19 cases of European ancestry after stratifying by the
presence of clinical risk factors.

(A) Rate of hospitalization in the AncestryDNA study (8,835 COVID-19 cases, including 636
hospitalized).

(B) Rate of hospitalization in the UK Biobank study (7,213 COVID-19 cases, including 1,824
hospitalized).

High genetic risk (red bars): top 10% of the GRS. Low genetic risk (grey bars): bottom 90% of the

GRS (*i.e.* all other COVID-19 cases).

Supplementary Figure 4. Association between a 3- and 8-SNP genetic risk score (GRS) and

risk of hospitalization and severe disease among COVID-19 cases of European ancestry. To

evaluate if the association between the GRS and worse disease outcomes was dependent on the

list of variants selected for analysis, we compared results between GRS calculated using different

sets of variants. We considered a GRS calculated using: (i) the three variants that were reported in

previous GWAS of COVID-19 susceptibility and that we validated the published association and

further showed that they were associated with risk of hospitalization or severe disease among

COVID-19 cases (in/near *LZTFL1*, MHC, *IFNAR2*; see **Figure 1A**); or (ii) all eight variants

reported in previous GWAS of COVID-19 susceptibility (in/near *LZTFL1* [two variants], MHC,

ABO, *OAS3*, *DPP9*, *RAVER1* and *IFNAR2*; see **Supplementary Table 5**). Analyses were

performed separately in the UK Biobank, AncestryDNA and GHS studies (risk of hospitalization

only) after stratifying COVID-19 cases by the presence of clinical risk factors, considering

individuals with lower clinical risk (blue circles), high clinical risk (green triangles) or all

individuals (grey squares). Association results were then meta-analyzed across studies.

SUPPLEMENTARY TABLES

Provided in a separate file.

Supplementary Table 1. Breakdown of COVID-19 status across the four studies included in

the analysis.

Supplementary Table 2. Demographics and clinical characteristics of study participants.

Supplementary Table 3. Definitions used for the seven COVID-19 phenotypes analyzed.

Supplementary Table 4. Genomic inflation factor (lambda) across the seven COVID-19

phenotypes analyzed.

Supplementary Table 5. Eight variants associated with COVID-19 susceptibility in previous

GWAS.

Supplementary Table 6. Association between eight published risk variants for COVID-19

and five disease susceptibility phenotypes in this study. P-values shown in red were significant

after correcting for the 40 tests performed ($P<0.00125$).

Supplementary Table 7. Comparison of effect sizes between ancestries for the five published

risk variants that were validated in this study.

Supplementary Table 8. Association between two severity phenotypes and five published

risk variants for COVID-19 that validated in this study.

Supplementary Table 9. Association between two severity phenotypes and two novel risk

variants for COVID-19 identified in this study.

Supplementary Table 10. Missense or predicted loss-of-function variants in high linkage

disequilibrium (LD, r^2>0.80) with sentinel GWAS variants.

Supplementary Table 11. Published gene expression datasets used to identify sentinel

expression quantitative trait loci (eQTL) in high LD (r^2>0.80) with sentinel GWAS variants.

Supplementary Table 12. Expression quantitative trait loci (eQTL) in high LD (r^2>0.80) with

sentinel GWAS variants.

Supplementary Table 13. Association between a three-SNP genetic risk score (GRS) and risk

of hospitalization among COVID-19 cases.

Supplementary Table 14. Association between a three-SNP genetic risk score (GRS) and risk

of severe disease among COVID-19 cases.

Supplementary Table 15. Association between a three-SNP genetic risk score (GRS) and

risk of hospitalization and severe disease among COVID-19 cases, after stratifying COVID-

19 cases by pre-existing clinical risk factor status for severe COVID-19.

References

1. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019.* New England Journal of Medicine, 2020. **382**(8): p. 727-733.
2. Coronaviridae Study Group of the International Committee on Taxonomy of, V., *The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.* Nat Microbiol, 2020. **5**(4): p. 536-544.
3. *World Health Organization Coronavirus Disease Weekly Epidemiological Update*. 2020; Available from: https://covid19.who.int/.
4. Guan, W.J., et al., *Clinical Characteristics of Coronavirus Disease 2019 in China.* N Engl J Med, 2020. **382**(18): p. 1708-1720.
5. Richardson, S., et al., *Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.* Jama, 2020. **323**(20): p. 2052-2059.
6. Atkins, J.L., et al., *PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-19 IN OLDER ADULTS IN THE UK BIOBANK COMMUNITY COHORT.* medRxiv, 2020: p. 2020.05.06.20092700.
7. Zhou, F., et al., *Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.* Lancet, 2020. **395**(10229): p. 1054-1062.
8. Cummings, M.J., et al., *Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.* Lancet, 2020. **395**(10239): p. 1763-1770.
9. Lopez, L., 3rd, L.H. Hart, 3rd, and M.H. Katz, *Racial and Ethnic Health Disparities Related to COVID-19.* JAMA, 2021.
10. Rochwerg, B., *A living WHO guideline on drugs for covid-19.* BMJ 2020;370:m3379 2020.
11. Group, R.C., et al., *Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.* N Engl J Med, 2020.
12. FDA, *Investigational COVID-19 Convalescent Plasma.* 2020.
13. *WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results*. medRxiv 2020; Available from: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1?ijkey=6ff7378035b 5c9c24346a6b90cadb5e866a63f71&keytype2=tf_ipsecsha.
14. Investigators, T.R.-C., *Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report.* bioRxiv, 2021.
15. Jackson, L.A., et al., *An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.* N Engl J Med, 2020. **383**(20): p. 1920-1931.
16. Walsh, E.E., et al., *Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.* N Engl J Med, 2020.
17. Hansen, J., et al., *Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.* Science, 2020. **369**(6506): p. 1010-1014.
18. Baum, A., et al., *Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.* Science, 2020. **369**(6506): p. 1014-1018.

19. *The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host*
genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J
Hum Genet, 2020. **28**(6): p. 715-718.
20. Ellinghaus, D., et al., *Genomewide Association Study of Severe Covid-19 with Respiratory*
Failure. New England Journal of Medicine, 2020.
21. Pairo-Castineira, E., et al., *Genetic mechanisms of critical illness in Covid-19.* Nature,
2020.
22. Shelton, J., F., Anjali J. Shastri, Chelsea Ye, Catherine H. Weldon, Teresa Filshtein-
Somnez, Daniella Coker, Antony Symons, Jorge Esparza-Gordillo, The 23andMe COVID-
19 Team, Stella Aslibekyan, Adam Auton, *Trans-ethnic analysis reveals genetic and non-*
genetic associations with COVID-19 susceptibility and severity. 2020.
23. Newman, D.M., et al., *Essential role for the histone acetyltransferase KAT7 in T cell*
development, fitness, and survival. J Leukoc Biol, 2017. **101**(4): p. 887-892.
24. Hoffmann, M., et al., *SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is*
Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020. **181**(2): p. 271-280 e8.
25. Hadjadj, J., et al., *Impaired type I interferon activity and inflammatory responses in*
severe COVID-19 patients. Science, 2020. **369**(6504): p. 718-724.
26. van der Made, C.I., et al., *Presence of Genetic Variants Among Young Men With Severe*
COVID-19. JAMA, 2020.
27. Zhang, Q., et al., *Inborn errors of type I IFN immunity in patients with life-threatening*
COVID-19. Science, 2020. **370**(6515).
28. Tervaniemi, M.H., et al., *Intracellular signalling pathways and cytoskeletal functions*
converge on the psoriasis candidate gene CCHCR1 expressed at P-bodies and
centrosomes. BMC Genomics, 2018. **19**(1): p. 432.
29. Ling, Y.H., et al., *CCHCR1 interacts with EDC4, suggesting its localization in P-bodies.* Exp
Cell Res, 2014. **327**(1): p. 12-23.
30. Olejnik-Schmidt, A.K., et al., *Search for cellular partners of human papillomavirus type 16*
E2 protein. Arch Virol, 2008. **153**(5): p. 983-90.
31. Muller, M. and C. Demeret, *CCHCR1 interacts specifically with the E2 protein of human*
papillomavirus type 16 on a surface overlapping BRD4 binding. PLoS One, 2014. **9**(3): p.
e92581.
32. Matsuura, K., M. Isogawa, and Y. Tanaka, *Host genetic variants influencing the clinical*
course of hepatitis B virus infection. J Med Virol, 2016. **88**(3): p. 371-9.
33. Kim, Y.J., et al., *A genome-wide association study identified new variants associated with*
the risk of chronic hepatitis B. Hum Mol Genet, 2013. **22**(20): p. 4233-8.
34. Lee, K.Y., et al., *Discovering Genetic Factors for psoriasis through exhaustively searching*
for significant second order SNP-SNP interactions. Sci Rep, 2018. **8**(1): p. 15186.
35. Szabo, P.A., et al., *Analysis of respiratory and systemic immune responses in COVID-19*
reveals mechanisms of disease pathogenesis. medRxiv, 2020.
36. Zhou, Z., et al., *Heightened Innate Immune Responses in the Respiratory Tract of COVID-*
19 Patients. Cell Host Microbe, 2020. **27**(6): p. 883-890 e2.
37. Merad, M. and J.C. Martin, *Pathological inflammation in patients with COVID-19: a key*
role for monocytes and macrophages. Nat Rev Immunol, 2020. **20**(6): p. 355-362.

38.   Aggarwal, N.R., L.S. King, and F.R. D'Alessio, *Diverse macrophage populations mediate*
580   *acute lung inflammation and resolution.* Am J Physiol Lung Cell Mol Physiol, 2014.
581   **306**(8): p. L709-25.

582   39.   Vuille-dit-Bille, R.N., et al., *Human intestine luminal ACE2 and amino acid transporter*
583   *expression increased by ACE-inhibitors.* Amino Acids, 2015. **47**(4): p. 693-705.

584   40.   Rollinger-Holzinger, I., et al., *LST1: a gene with extensive alternative splicing and*
585   *immunomodulatory function.* J Immunol, 2000. **164**(6): p. 3169-76.

586   41.   Mulcahy, H., et al., *LST1 and NCR3 expression in autoimmune inflammation and in*
587   *response to IFN-gamma, LPS and microbial infection.* Immunogenetics, 2006. **57**(12): p.
588   893-903.

589   42.   Apps, R., et al., *Influence of HLA-C expression level on HIV control.* Science, 2013.
590   **340**(6128): p. 87-91.

591   43.   Kulkarni, S., et al., *Genetic interplay between HLA-C and MIR148A in HIV control and*
592   *Crohn disease.* Proc Natl Acad Sci U S A, 2013. **110**(51): p. 20705-10.

593   44.   Begue, B., et al., *Defective IL10 signaling defining a subgroup of patients with*
594   *inflammatory bowel disease.* Am J Gastroenterol, 2011. **106**(8): p. 1544-55.

595   45.   Frodsham, A.J., et al., *Class II cytokine receptor gene cluster is a major locus for hepatitis*
596   *B persistence.* Proc Natl Acad Sci U S A, 2006. **103**(24): p. 9148-53.

597   46.   Bottcher, E., et al., *Proteolytic activation of influenza viruses by serine proteases*
598   *TMPRSS2 and HAT from human airway epithelium.* J Virol, 2006. **80**(19): p. 9896-8.

599   47.   Kleine-Weber, H., et al., *Functional analysis of potential cleavage sites in the MERS-*
600   *coronavirus spike protein.* Sci Rep, 2018. **8**(1): p. 16597.

601   48.   Matsuyama, S., et al., *Efficient activation of the severe acute respiratory syndrome*
602   *coronavirus spike protein by the transmembrane protease TMPRSS2.* J Virol, 2010.
603   **84**(24): p. 12658-64.

604   49.   Iwata-Yoshikawa, N., et al., *TMPRSS2 Contributes to Virus Spread and Immunopathology*
605   *in the Airways of Murine Models after Coronavirus Infection.* J Virol, 2019. **93**(6).

606   50.   Vaser, R., et al., *SIFT missense predictions for genomes.* Nat Protoc, 2016. **11**(1): p. 1-9.

607   51.   Adzhubei, I., D.M. Jordan, and S.R. Sunyaev, *Predicting functional effect of human*
608   *missense mutations using PolyPhen-2.* Curr Protoc Hum Genet, 2013. **Chapter 7**: p.
609   Unit7.20.

610   52.   Vishnubhotla R., V., N., et al. , *Genetic variants in TMPRSS2 and Structure of SARS-CoV-2*
611   *spike glycoprotein and TMPRSS2 complex.* bioRxiv, 2020.

612   53.   David, A., Khanna, T., Beykou, M., Hanna, G., Sternberg, M. J. E., *Structure, function and*
613   *variants analysis of the androgen-regulated TMPRSS2, a drug target candidate for*
614   *COVID-19 infection.* bioRxiv, 2020.

615   54.   *How CDC Is Making COVID-19 Vaccine Recommendations*. 2020 [cited 2020 December
616   2, 2020]; Available from: https://www.cdc.gov/coronavirus/2019-
617   ncov/vaccines/recommendations-process.html.

618   55.   Roberts, G.H.L., *AncestryDNA COVID-19 Host Genetic Study Identifies Three Novel Loci.*
619   medRxiv, 2020.

620   56.   Dewey, F.E., et al., *Distribution and clinical impact of functional variants in 50,726*
621   *whole-exome sequences from the DiscovEHR study.* Science, 2016. **354**(6319).

622   57.   Park, J., et al., *A genome-first approach to aggregating rare genetic variants in LMNA for*
623   *association with electronic health record phenotypes.* Genet Med, 2020. **22**(1): p. 102-
624   111.
625   58.   Bycroft, C., et al., *The UK Biobank resource with deep phenotyping and genomic data.*
626   Nature, 2018. **562**(7726): p. 203-209.
627   59.   Mbatchou, J., et al., *Computationally efficient whole genome regression for quantitative*
628   *and binary traits.* bioRxiv, 2020: p. 2020.06.19.162354.
629   60.   Ferreira, M.A., et al., *Shared genetic origin of asthma, hay fever and eczema elucidates*
630   *allergic disease biology.* Nat Genet, 2017. **49**(12): p. 1752-1757.
631   61.   Chun, S., et al., *Limited statistical evidence for shared genetic effects of eQTLs and*
632   *autoimmune-disease-associated loci in three major immune-cell types.* Nat Genet, 2017.
633   **49**(4): p. 600-605.
634